Merck’sVytorin may reduce CV events in CKD
This article was originally published in Scrip
Merck & Co's Vytorin (ezetimibe/simvastatin) reduced the incidence of first major vascular events – defined as non-fatal heart attacks or cardiac death, stroke or any revascularisation procedure – by 16% in patients with chronic kidney disease (CKD), according to data from the five-year SHARP study.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.